Learn More
BACKGROUND A high prevalence (52%) of hyperhomocysteinemia is observed in Crohn disease (CD), however it is not well documented in ulcerative colitis (UC). Furthermore, in the different works studying hyperhomocysteinemia the associated factors are different. AIM Prospective evaluation of hyperhomocysteinemia in inflammatory bowel disease (IBD) patients,(More)
BACKGROUND Antibodies to infliximab [ATI] and trough levels to infliximab [TRI] are associated with loss of response in inflammatory bowel diseases [IBD]. The best way to predict loss of response [LOR] to infliximab [IFX] is unknown. METHODS We conducted a prospective observational cohort study enrolling all IBD patients who were in clinical remission at(More)
BACKGROUND A drug interaction has been observed between infliximab and methotrexate in rheumatoid arthritis. AIM To look for an interaction between infliximab and azathioprine in Crohn's disease patients using the active metabolites of azathioprine: 6-tioguanine nucleotides. METHODS Patients receiving azathioprine who required infliximab for(More)
BACKGROUND A high prevalence of osteoporosis is observed in Crohn's disease. Recent data have shown that homocysteinaemia is an important risk factor in low-bone mineralization and fracture. AIM To look for an association between homocysteinaemia and low-bone mineralization in Crohn's disease patients. PATIENTS AND METHODS Ninety-two consecutive(More)
BACKGROUND Although the use of tumour necrosis factor (TNF) antagonists is increasingly codified, several unresolved issues remain. AIM To conduct a French national survey on TNF antagonists use in inflammatory bowel disease (IBD). METHODS A postal questionnaire was sent to all French gastroenterologists among whom 450 prescribe TNF antagonists for IBD.(More)
OBJECTIVES Several decision algorithms based on the measurement of infliximab (IFX) trough levels and antibodies to IFX have been proposed. Whether such algorithms can be extrapolated to the pharmacokinetics of adalimumab (ADA) has yet to be determined. METHODS A prospective study included all consecutive patients with inflammatory bowel disease (IBD)(More)
BACKGROUND 6-Thioguanine (6-tioguanine) nucleotides are the active metabolites of azathioprine. AIM The aim of the study was to evaluate the rate of clinical remission without steroids in steroid-dependent Crohn's disease and ulcerative colitis patients receiving azathioprine, the medium- and long-term efficacy and the predictive factors of clinical(More)